Skip to contentS
Spyre Therapeutics, Inc.
S
SYRESpyre Therapeutics, Inc. Q3 2022 · 10-Q
Revenue$174.00K$174.00K−87.6% vs Q3 2021 Net Income-$18.23M-$18.23MN/M vs Q3 2021 EPS Diluted-$4.84-$4.84N/M vs Q3 2021 Operating Income-$18,755,000N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Spyre Therapeutics, Inc. · CIK 1636282 · Engraved from SEC EDGAR
derived
Free Cash Flowderived-$15,069,000N/M Margins · derivedOperating margin-10778.7%−9328.2 pt vs Q3 2021
Net margin-10479.3%−9027.8 pt vs Q3 2021
ended Sep 30, 2022 · filed Nov 3, 2022 · 34 d after period end